Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions

doi:10.3748/wjg.v23.i32.5875

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 23, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11697)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

1128

WORD

216

HTML

7776

Figures (1-1)

199

Tables (1-3)

168

Sum=9487

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1058

Download

1152

Sum=2210

Aug 28, 2017 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (69)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Aug 28, 2017; 23(32): 5875-5886
Published online Aug 28, 2017. doi: 10.3748/wjg.v23.i32.5875

Table 1 Patients characteristics in metastatic pancreatic cancer pivotal trials

	Gemcitabine	FOLFIRINOX	Nab-paclitaxel + gemcitabine
Trial (yr)	Gemcitabine vs 5-fluorouracil (1997)	FOLFIRINOX vs Gemcitabine (2011)	Nab-paclitaxel + Gemcitabine vs Gemcitabine (2013)
Phase	¹	II-III	III
Countries	United states-Canada-United Kingdom	France	Worldwide
Patients	126	342	861
Median age	61.5	61	62
Elderly ( ≥ 75 yr)	Yes		Yes
ECOG PS 0-1	Yes	Yes	Yes
ECOG PS 2	Yes		Yes
Biliary Stent	Yes	Yes	Yes
Multiple metastatic sites	Yes	Yes	Yes

¹Phase not specified in the full paper. ECOG PS: Eastern Cooperative Oncology Group Performance Status.

Citation: Giordano G, Pancione M, Olivieri N, Parcesepe P, Velocci M, Di Raimo T, Coppola L, Toffoli G, D’Andrea MR. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions. World J Gastroenterol 2017; 23(32): 5875-5886
URL: https://www.wjgnet.com/1007-9327/full/v23/i32/5875.htm
DOI: https://dx.doi.org/10.3748/wjg.v23.i32.5875